The European Medicines Agency’s safety committee has issued a new warning against using topiramate, a drug commonly used to treat epilepsy and migraines, during pregnancy.
The committee launched a review last year into a potential increased risk of neurodevelopmental disorders in children exposed to topiramate in the womb. On Friday, its Pharmacovigilance Risk Assessment Committee (PRAC) said pregnant women should not take the drug to prevent migraine or manage body weight, and should only use it for the treatment of epilepsy if there are no other options.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.